Prescient Therapeutics Ltd has released a press release.
Continued promising results in PTX-100 TCL trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- FDA grants broader orphan drug status to PTX100 for TCLs
- December 2022 Quarterly Update and Appendix 4C
- AGM Presentation
- September 2022 Quarterly Update and Appendix 4C
- PTX-100 Trial Update
Later from Prescient Therapeutics
- March 2023 Quarterly Update and Appendix 4C
- June 2023 Quarterly Update and Appendix 4C
- Appendix 4E and 2023 Annual Report
- September 2023 Quarterly Update and Appendix 4C
- PTX-100 Ph1b results show excellent safety & efficacy in TCL
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics